immatics biotechnologies GmbH Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| ARISTEIA CAPITAL LLC | 11/14/2024 | 832,328 | $1.94 M | 0.00% | 0.81% |
| FORT BAKER CAPITAL MANAGEMENT LP | 11/14/2024 | 790,094 | $1.82 B | -0.86% | 0.77% |
| LMR PARTNERS LLP | 11/07/2024 | 541,825 | $1.25 M | 100.00% | 0.53% |
| SOFINNOVA INVESTMENTS, INC. | 11/13/2024 | 366,568 | $852.27 M | 5.11% | 0.36% |
| 683 CAPITAL MANAGEMENT, LLC | 11/14/2024 | 348,032 | $800,474 | -0.03% | 0.34% |
| D. E. SHAW & CO., INC. | 11/14/2024 | 330,023 | $759,053 | 0.00% | 0.32% |
| AEQUIM ALTERNATIVE INVESTMENTS LP | 11/15/2024 | 252,741 | $581,304 | 0.00% | 0.25% |
| NANTAHALA CAPITAL MANAGEMENT, LLC | 11/14/2024 | 248,506 | $571,564 | 0.00% | 0.24% |
| AFFINITY ASSET ADVISORS, LLC | 11/13/2024 | 187,204 | $430,569 | 0.00% | 0.18% |
| WALLEYE CAPITAL LLC | 11/14/2024 | 184,318 | $423,931 | -1.00% | 0.18% |
| SPHERA FUNDS MANAGEMENT LTD. | 11/14/2024 | 100,000 | $230,000 | 0.00% | 0.10% |
| TWO SIGMA INVESTMENTS, LP | 11/14/2024 | 87,700 | $201,710 | 0.00% | 0.09% |
| BOOTHBAY FUND MANAGEMENT, LLC | 11/14/2024 | 77,094 | $879,643 | 0.00% | 0.07% |
| WOLVERINE ASSET MANAGEMENT LLC | 11/04/2024 | 46,765 | $107,559 | 14.58% | 0.05% |
| WEISS ASSET MANAGEMENT LP | 11/14/2024 | 40,065 | $92,150 | 0.00% | 0.04% |
| JPMORGAN CHASE & CO | 12/26/2024 | 0 | $0 | -100.00% | 0.00% |
| LMR PARTNERS LLP | 11/07/2024 | 0 | $0 | -100.00% | 0.00% |
| UBS GROUP AG | 11/14/2024 | 0 | $0 | -100.00% | 0.00% |
| PRIVIUM FUND MANAGEMENT B.V. | 11/01/2024 | 0 | $0 | -100.00% | 0.00% |
immatics biotechnologies GmbHinstitutional Ownership - FAQ's
During the previous two years, 20 institutional investors and hedge funds held shares of immatics biotechnologies GmbH. The most heavily invested institutionals were:
ARISTEIA CAPITAL LLC: 832,328
Fort Baker Capital Management LP: 790,094
Sofinnova Investments, Inc.: 366,568
683 Capital Management, LLC: 348,032
D. E. Shaw & Co., Inc.: 330,023
Aequim Alternative Investments LP: 252,741
3.78% of immatics biotechnologies GmbH stock is owned by institutional investors.
Institutional investors have bought a total of 4.08 M shares in the last 24 months. This purchase volume represents approximately $203,844 in transactions.